NEXTGEN BIOMED LTD Inactive Instrument
Nextgen Biomed Ltd Stock TEL AVIV STOCK EXCHANGE
Equities
NXGN
IL0010839301
Medical Equipment, Supplies & Distribution
| Sales 2022 | - | Sales 2023 | - | Capitalization | 9.19M 33.38M |
|---|---|---|---|---|---|
| Net income 2022 | -8M -29.06M | Net income 2023 | -14M -50.85M | EV / Sales 2022 | - |
| Net cash position 2022 | 5.24M 19.03M | Net cash position 2023 | 65K 236K | EV / Sales 2023 | - |
| P/E ratio 2022 |
-3.17
x | P/E ratio 2023 |
-0.65
x | Employees | - |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 92.06% |
More Fundamentals
* Assessed data
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 49 | 22-11-19 | |
Dalia Mulakandov
DFI | Director of Finance/CFO | 40 | 23-01-16 |
Daniel Spira
AUD | Comptroller/Controller/Auditor | 70 | 00-08-07 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
David Grossman
BRD | Director/Board Member | 49 | 22-06-11 |
Yaacov Amidror
CHM | Chairman | 76 | 21-01-06 |
Alon Pinkas
BRD | Director/Board Member | 62 | 22-11-16 |
Nextgen Biomed Ltd is an Israel-based research and development company. Its main activity is to own EyePen product. The Company's product is dedicated to people with diabetes and consists of an injection module which allows to monitor the doses and time of insulin intake. The EyePen mobile app keeps diabetes management systematic by monitoring behavior and provides alerts for human errors such as forgetting a pen, double insulin injections, or skipping injections.
| 1st Jan change | Capi. | |
|---|---|---|
| +11.30% | 28.56B | |
| +23.33% | 2.57B | |
| +28.15% | 2.53B | |
| -48.23% | 2.32B | |
| +35.56% | 2.09B | |
| -31.22% | 2.06B | |
| -24.21% | 1.6B | |
| +13.16% | 1.45B | |
| +31.35% | 1.33B |
